Personalis (NASDAQ:PSNL) Sets New 12-Month High – Still a Buy?

Personalis, Inc. (NASDAQ:PSNL) shares reached a new 52-week high on Thursday . The stock traded as high as $12.74 and last traded at $12.7180, with a volume of 1213241 shares traded. The stock had previously closed at $11.36.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on PSNL shares. Morgan Stanley decreased their target price on Personalis from $10.00 to $9.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 12th. Needham & Company LLC increased their price target on Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. BTIG Research cut their price target on Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Monday, May 11th. Wall Street Zen lowered Personalis from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a research note on Tuesday, April 21st. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $11.00.

Personalis Stock Performance

The business has a 50 day simple moving average of $8.42 and a 200-day simple moving average of $8.29. The stock has a market capitalization of $1.36 billion, a P/E ratio of -12.76 and a beta of 2.28.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). The firm had revenue of $15.47 million during the quarter, compared to the consensus estimate of $14.48 million. Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%. Equities research analysts forecast that Personalis, Inc. will post -1.06 EPS for the current fiscal year.

Insider Activity

In other news, CEO Christopher M. Hall sold 100,000 shares of the firm’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $13.15, for a total transaction of $1,315,000.00. Following the completion of the transaction, the chief executive officer owned 235,986 shares in the company, valued at approximately $3,103,215.90. This trade represents a 29.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 51,251 shares of Personalis stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $13.18, for a total transaction of $675,488.18. Following the completion of the transaction, the chief financial officer directly owned 198,833 shares in the company, valued at $2,620,618.94. This represents a 20.49% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 330,050 shares of company stock worth $4,022,181. 4.20% of the stock is owned by company insiders.

Institutional Trading of Personalis

A number of large investors have recently added to or reduced their stakes in the business. Royal Bank of Canada increased its holdings in shares of Personalis by 3.2% in the first quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock valued at $275,000 after buying an additional 2,395 shares in the last quarter. Dynamic Technology Lab Private Ltd boosted its stake in shares of Personalis by 75.6% during the 1st quarter. Dynamic Technology Lab Private Ltd now owns 76,729 shares of the company’s stock worth $269,000 after acquiring an additional 33,044 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Personalis by 55.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 284,426 shares of the company’s stock worth $998,000 after acquiring an additional 101,706 shares in the last quarter. Focus Partners Wealth acquired a new position in shares of Personalis in the 1st quarter worth $47,000. Finally, JPMorgan Chase & Co. grew its holdings in shares of Personalis by 505.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 29,491 shares of the company’s stock worth $193,000 after acquiring an additional 24,621 shares during the last quarter. 61.91% of the stock is currently owned by institutional investors.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.